



The unexpected and unresolved roles of *PDGFRA* and *PDGFRB* in T-cell acute lymphoblastic leukemia

by Krista Verhoeft and Jan Cools

Received: January 26, 2024.

Accepted: February 15, 2024.

Citation: Krista Verhoeft and Jan Cools.

The unexpected and unresolved roles of PDGFRA and PDGFRB in T-cell acute lymphoblastic leukemia. *Haematologica*. 2024 Feb 22. doi: 10.3324/haematol.2023.284524 [Epub ahead of print]

Publisher's Disclaimer.

E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.

E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.

The unexpected and unresolved roles of *PDGFRA* and *PDGFRB* in T-cell acute lymphoblastic leukemia

Krista Verhoeft,^{1,2} Jan Cools^{1,2}

¹ Center for Human Genetics, KU Leuven, Leuven, Belgium

² Center for Cancer Biology, Leuven, Belgium

Corresponding author: Jan Cools – jan.cools@kuleuven.be

Platelet-derived growth factor (PDGF) has been investigated for over 50 years. Despite the numerous detailed studies about the PDGF growth factors and their receptors *PDGFRA* and *PDGFRB* in health and disease, new findings, such as those reported by the group of Pieter Van Vlierberghe in this issue of *Haematologica*,¹ keep surprising us about the diverse roles of these receptors in various cancers.

The platelet-derived growth factor receptor (PDGFR) family comprises a group of receptor tyrosine kinases with a characteristic split kinase domain. For the fascinating story about the discovery and cloning of PDGF and its receptors in the 1970s and 1980s, we refer to the review article by Bowen-Pope and Raines.² Interestingly, the PDGFR family does not only include *PDGFR α* and *PDGFR β* , but also *FLT3*, *KIT* and the *CSF1R* receptors, which all have very similar structures. Ligand binding causes homo- or heterodimerization of the receptor, which activates the kinase domains and leads to phosphorylation of the receptors as well as a variety of signaling proteins.³

All of these receptors are implicated in cancer development, either by being directly mutated and actively driving cancer development or by a role in angiogenesis, one of the hallmarks of solid tumors. The *PDGFRA*, *PDGFRB*, *FLT3* and *KIT* genes are now well known for their roles in various hematological malignancies. The *ETV6-PDGFRB* fusion gene was one of the first identified oncogenes in this family in myeloid neoplasms often associated with eosinophilia. Since then, many other *PDGFRB* fusions have been identified with numerous fusion partners. Later, internal tandem duplications (ITDs) were observed in *FLT3* in AML, *KIT* mutations were identified in systemic mastocytosis and the *FIP1L1-PDGFR α* fusion was identified as a cryptic but recurrent fusion gene in chronic eosinophilic leukemia.⁵⁻⁷ In solid tumors, *PDGFRA* or *PDGFRB* amplification/overexpression are often found and in gastrointestinal tumors mutant *PDGFRA* or mutant *KIT* are important oncogenic drivers.⁸

In acute lymphoblastic leukemia (ALL), however, *PDGFRA* or *PDGFRB* alterations were to date only detected in few isolated cases, including in Ph-like ALL and in few T-ALL cases.^{9,10} In this issue of *Haematologica*, the group of Pieter Van Vlierberghe identified an *MYH9-PDGFRB* fusion gene in one case of T-lymphoblastic lymphoma (T-LBL). Moreover, upon subsequent further exploration in T-ALL, they identified expression and phosphorylation of *PDGFR β* in several T-ALL cases.¹ Surprisingly, another group recently described *PDGFRA* fusion genes in relapsed/refractory T-ALL.¹¹ Although there have been some previous indications that *PDGFRA/B* could be rearranged in T-cell malignancies, these recent studies definitively identify activated *PDGFR α* and *PDGFR β* as drivers of T-ALL and T-LBL and as possible therapeutic targets in T-cell malignancies.

In the study of the Van Vlierberghe group, the authors initially studied the oncogenic potential of *MYH9-PDGFR β* in cell and mouse models.¹ In line with previous reports on *PDGFR β* fusion proteins, *MYH9-PDGFR β* showed auto-phosphorylation, activation of downstream signaling proteins such as *STAT5*, and transformed Ba/F3 cells to growth factor independent growth. In addition, expression of this fusion gene in bone marrow cells of mice

resulted in the rapid development of myeloid or T-cell malignancies with accumulation of Gr1⁺/Cd11b⁺ myeloid cells or Cd4⁺/Cd8⁺ lymphoid cells, respectively. The development of both myeloid and lymphoid malignancies in the mouse model is similar to what has been observed with other oncogenic tyrosine kinases and is also dependent on the mouse strain that is used. Finally, the authors also demonstrated efficacy of a selective PDGFR β inhibitor to reduce the leukemia burden *in vivo* using a patient-derived T-ALL xenograft model with a T-ALL sample that showed PDGFR β activation.

Surprisingly, further analysis of T-ALL PDX samples by Western blotting revealed expression and phosphorylation of PDGFR β in 4 of 11 T-ALL cases.¹ Intriguingly, the exact cause of the elevated PDGFR β protein levels and auto-phosphorylation could not be attributed to mutations or other obvious genomic changes, and thus remains to be solved. These elevated PDGFR β protein levels may not be always detectable at RNA level and could thus be missed if only RNA-seq data are analyzed. Further studies are warranted to explore the sensitivity of T-ALL cases to PDGFR β inhibitors. Moreover, in an independent study by Paolino et al. on relapsed/refractory T-ALL/T-LBL cases, these authors identified 3 of 14 cases with alterations of the PDGFRA gene.¹¹ Here they found 2 cases with the *FIP1L1-PDGFR*A fusion and one case with the D842V mutation in *PDGFRA*.

These recurrent *PDGFRA* and *PDGFRB* aberrations in T-ALL/T-LBL indicate that existing PDGFR kinase inhibitors could be tested in relapsed cases for which no other effective therapies exist.^{1,11} Imatinib is the oldest inhibitor (already off patent) that could be explored, since this inhibitor has very little side effects and is a very potent PDGFR kinase inhibitor.⁷ However, it is already known that the D842V mutations in *PDGFRA* causes resistance to imatinib, and in such cases sorafenib or other newer kinase inhibitors are needed.⁸

This work was initiated by Pieter Van Vlierberghe, but unfortunately he did not get the chance to complete the study and witness how this work could influence further research and be applied in the clinic.¹² Pieter was an extraordinary scientist and very committed collaborator. He would do the impossible to contribute to other projects worldwide. Advancing T-ALL research to improve patient care was close to his heart.

As also demonstrated in this study here,¹ Pieter had a talent to identify unique leukemia cases with interesting genomic alterations and then start from such observations to study that in larger cohorts. This work often led to fantastic new discoveries, such as the identification of the *PHF6* mutations in T-ALL. In that work, Pieter started from few isolated cases with *PHF6* deletions and finally discovered that *PHF6* is one of the most frequently mutated genes in T-ALL.¹³

It is now more than one year ago that Pieter passed away after a courageous fight over several years during which he remained active in the field, contributed to studies, led his own research lab and obtained research funding. He was a 'warrior', a 'soldier' and a 'champion', as in the lyrics of one of his favorite songs by 'Oscar and the Wolf'. "They say that I'm gonna be a star one day". We all miss him so much, but his contribution to T-ALL research and clinical practice is continuing to make changes and will forever.

References

1. De Coninck S, De Smedt R, Lintermans B, et al. Targeting hyperactive platelet-derived growth factor receptor- β signaling in T-cell acute lymphoblastic leukemia and lymphoma. *Haematologica*. xxx
2. Bowen-Pope DF, Raines EW. History of discovery: platelet-derived growth factor. *Arterioscler Thromb Vasc Biol*. 2011;31(11):2397-2401.
3. Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. *Cell Commun Signal*. 2013;11:97.
4. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. *Cell*. 1994;77(2):307-316.
5. Ambinder AJ, Levis M. Potential targeting of FLT3 acute myeloid leukemia. *Haematologica*. 2021;106(3):671-681.
6. Valent P, Akin C, Hartmann K, et al. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. *Hemasphere*. 2021;5(11):e646.
7. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med*. 2003;348(13):1201-1214.
8. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. *Gastroenterology*. 2005;128(2):270-279.
9. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. *N Engl J Med*. 2014;371(11):1005-1015.
10. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFR α fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. *Leukemia*. 2007;21(6):1183-1188.
11. Paolino J, Dimitrov B, Apsel Winger B, et al. Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. *Clin Cancer Res*. 2023;29(22):4613-4626.
12. Dawidowska M, Dzikiewicz-Krawczyk A, Rozwadowska N, et al. Obituary—Pieter Van Vlierberghe (1980–2022). *Leukemia*. 2023;37:952-953.
13. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. *Nat Genet*. 2010;42(4):338-342.